2.33
0.09 (4.02%)
| Penutupan Terdahulu | 2.24 |
| Buka | 2.29 |
| Jumlah Dagangan | 509,460 |
| Purata Dagangan (3B) | 1,687,201 |
| Modal Pasaran | 148,137,968 |
| Harga / Buku (P/B) | 6.50 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 15 May 2026 |
| EPS Cair (TTM) | -0.960 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.67% |
| Nisbah Semasa (MRQ) | 3.00 |
| Aliran Tunai Operasi (OCF TTM) | -15.63 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -15.19 M |
| Pulangan Atas Aset (ROA TTM) | -90.68% |
| Pulangan Atas Ekuiti (ROE TTM) | -332.67% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | TuHURA Biosciences, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 0.5 |
| Purata | 0.38 |
|
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 41.96% |
| % Dimiliki oleh Institusi | 8.43% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Suncoast Equity Management | 31 Dec 2025 | 104,409 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |